Advertisement
UK markets close in 8 hours 13 minutes
  • FTSE 100

    7,950.89
    +18.91 (+0.24%)
     
  • FTSE 250

    19,802.66
    -8.00 (-0.04%)
     
  • AIM

    742.11
    0.00 (0.00%)
     
  • GBP/EUR

    1.1683
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • Bitcoin GBP

    55,768.73
    +273.26 (+0.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.86
    +0.51 (+0.63%)
     
  • GOLD FUTURES

    2,212.00
    -0.70 (-0.03%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,558.25
    +165.41 (+1.01%)
     
  • DAX

    18,485.62
    +8.53 (+0.05%)
     
  • CAC 40

    8,216.60
    +11.79 (+0.14%)
     

The Independent Director of National Health Investors, Inc. (NYSE:NHI), Robert Adams, Just Bought A Few More Shares

Even if it's not a huge purchase, we think it was good to see that Robert Adams, the Independent Director of National Health Investors, Inc. (NYSE:NHI) recently shelled out US$57k to buy stock, at US$56.60 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

See our latest analysis for National Health Investors

National Health Investors Insider Transactions Over The Last Year

In fact, the recent purchase by Independent Director Robert Adams was not their only acquisition of National Health Investors shares this year. Earlier in the year, they paid US$57.25 per share in a US$115k purchase. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$54.62). It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Robert Adams.

ADVERTISEMENT

Robert Adams bought a total of 4.50k shares over the year at an average price of US$60.00. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

National Health Investors is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does National Health Investors Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It's great to see that National Health Investors insiders own 4.3% of the company, worth about US$101m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Does This Data Suggest About National Health Investors Insiders?

It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about National Health Investors. One for the watchlist, at least! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To help with this, we've discovered 4 warning signs (1 is concerning!) that you ought to be aware of before buying any shares in National Health Investors.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here